Summary
PHOO Chart
Photocure ASA (PHOO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Photocure ASA ever had a stock split?
Photocure ASA Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Daniel Schneider CEO | XSTO Exchange | NO0010000045 ISIN |
| NO Country | 99 Employees | 23 May 2013 Last Dividend | - Last Split | - IPO Date |
Overview
Photocure ASA is a specialty pharmaceutical company that has carved a niche for itself in the research, development, production, distribution, marketing, and sale of pharmaceutical products, with a significant presence across Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. Established in 1993 and headquartered in Oslo, Norway, the company specializes in addressing critical needs in the diagnosis and treatment of bladder cancer and other serious medical conditions. Leveraging its extensive network, Photocure ASA delivers its innovative products to pharmaceutical wholesalers, pharmacies, and hospitals, primarily through licensing partnerships that extend its global reach and efficacy in the healthcare market.
Products and Services
- Hexvix/Cysview:
Hexvix/Cysview represents Photocure ASA's flagship product, offering a groundbreaking solution for the detection and management of bladder cancer. This innovative diagnostic tool enhances the visibility of cancerous cells during bladder examination procedures, thereby significantly improving the accuracy and effectiveness of bladder cancer management strategies. As a leader in photodynamic diagnosis, Hexvix/Cysview has transformed the approach towards bladder cancer diagnosis and treatment, contributing to more precise and beneficial patient care.
- Cevira:
Cevira is another testament to Photocure ASA's commitment to advancing healthcare through innovation. Currently under development, Cevira is a promising treatment for human papilloma virus (HPV) infection and precancerous lesions of the cervix. This therapeutic candidate embodies the company's dedication to addressing widespread health issues, with the potential to offer a non-invasive treatment option that could revolutionize the management of HPV-related conditions and cervical precancer. By targeting the root causes of cervical abnormalities, Cevira underscores Photocure ASA's mission to develop solutions that not only treat but also potentially prevent the progression of serious diseases.
